Clinical Trial Update: A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing Gimsilumab for efficacy and safety in COVID-19–related lung injury and ARDS; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Gimsilumab (Gimsilumab)

Snippet

Sponsor: Kinevant Sciences GmbH | Conditions: COVID-19 | Phase 2 | Status: COMPLETED | Results posted: 2021-12-10